An oral formulation of Marinus Pharmaceuticals, Inc.’s ganaxolone has met its primary endpoint in the Phase III MARIGOLD study in patients with an rare, genetic form of severe epilepsy, markedly reducing the seizure frequency. The results are a boost for the GABA-A modulator, which has previously reported disappointing mid-stage clinical trial results in another indication, post-partum depression.
Marketing submissions are planned for the US in the middle of next year, and in the EU in the third...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)